(R)-CR8

Name: (R)-CR8
SKU: C6800
Availability: InStock

Product ID C6800

Cas No. 294646-77-8

Purity ≥98%

Product Unit Size	Cost	Quantity		Stock

Bulk Quote

Add to Wishlist

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description

(R)-CR8 is an analog of roscovitine that inhibits cyclin-dependent kinases (CDKs) 1/2/3/5/7/9; it displays anticancer and neuroprotective activities. (R)-CR8 induces apoptosis and downregulates expression of Mcl-1 in neuroblastoma cells. In chromic myelogenous leukemia (CML) cells, (R)-CR8 inhibits cell cycle progression. In animal models of spinal cord injury, this compound decreases neurodegeneration, cognitive decline, and microglial activation. CR8 also decreases sensorimotor deficits, cognitive deficits, and lesion volume by limiting cell cycle activation in animal models of traumatic brain injury.

Product Info

Cas No.	294646-77-8
Purity	≥98%
Formula	C₂₄H₂₉N₇O
Formula Wt.	431.54
Chemical Name	2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-(4-(2-pyridyl)benzyl)-9-isopropylpurine
IUPAC Name	(2R)-2-[(9-Isopropyl-6-{[4-(2-pyridinyl)benzyl]amino}-9H-purin-2-yl)amino]-1-butanol
Solubility	Soluble in DMSO or 100% ethanol
Appearance	White to off-white solid

Shipping and Storage

Store Temp	-20°C
Ship Temp	Ambient

Downloads

MSDS	C6800 MSDS PDF
Info Sheet	C6800 Info Sheet PDF

References

Troadec S, Blairvacq M, Oumata N, et al. Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines. J Biomed Sci. 2015 Jul 17;22:57. PMID: 26184865.

Wu J, Zhao Z, Sabirzhanov B, et al. Spinal cord injury causes brain inflammation associated with cognitive and affective changes: role of cell cycle pathways. J Neurosci. 2014 Aug 13;34(33):10989-1006. PMID: 25122899.

Kabadi SV, Stoica BA, Loane DJ, et al. CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury. J Cereb Blood Flow Metab. 2014 Mar;34(3):502-13. PMID: 24398934.

Bettayeb K, Baunbæk D, Delehouze C, et al. CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. Genes Cancer. 2010 Apr;1(4):369-80. PMID: 21779453.

Bettayeb K, Oumata N, Echalier A, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008 Oct 2;27(44):5797-807. PMID: 18574471.